Hong-xia Zhu

ORIGINAL ARTICLE: Mifepristone as an Anti‐Implantation Contraceptive Drug: Roles in Regulation of Uterine Natural Killer Cells during Implantation Phase

Yaling Zhuang, Lili Huang, Wuwen Zhang, 2008, American journal of reproductive immunology.

AMLnet, A deep-learning pipeline for the differential diagnosis of acute myeloid leukemia from bone marrow smears

Yingli Han, P. Qian, He Huang, 2023, Journal of Hematology & Oncology.

Homoharringtonine Synergizes Strongly with Venetoclax Against the Early T-Cell Progenitor Acute Lymphoblastic Leukemia：from Bench to Bed

L. Ghoda, G. Marcucci, Min Yang, 2022, Blood.

A Predictor Combining Clinical and Genetic Factors for AML1-ETO Leukemia Patients

Min Yang, Jian Huang, Chao Hu, 2022, Frontiers in Oncology.

The clinical impact of IKZF1 mutation in acute myeloid leukemia

Min Yang, Jianmin Yang, G. Tang, 2023, Experimental Hematology & Oncology.

Ruxolitinib combined with dexamethasone in adult patients with newly diagnosed Hemophagocytic lymphohistiocytosis: A single‐center pilot trial

H. Tong, Lixia Zhu, Xin Huang, 2023, American journal of hematology.

A global study for acute myeloid leukemia with RARG rearrangement

J. Welch, H. Kantarjian, Jiong Hu, 2023, Blood advances.

15‐days duration of venetoclax combined with azacitidine in the treatment of relapsed/refractory high‐risk myelodysplastic syndromes: A retrospective single‐center study

Yingwan Luo, Haiyang Yang, Xinping Zhou, 2022, Hematological oncology.

Advances in clinical studies of FLT3 inhibitors in acute myeloid leukemia.

W. Yuan, Hong-xia Zhu, Shizhong Zhang, 2022, Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences.

Homoharringtonine synergizes with venetoclax in early T cell progenitor acute lymphoblastic leukemia: Bench and bed.

Fengling Li, L. Nguyen, Dinh Hoa Hoang, 2024, Med.